Alnylam Pharmaceuticals
ALNY
#616
Rank
NZ$69.78 B
Marketcap
NZ$522.67
Share price
-0.19%
Change (1 day)
3.57%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$6.60

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$6.54. In 2025 the company made an earnings per share (EPS) of NZ$3.10.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.60112.64%
2025NZ$3.10
2023NZ-$6.09-62%
2022NZ-$16.0229.03%
2021NZ-$12.42-3.36%
2020NZ-$12.85-8.48%
2019NZ-$14.047.67%
2018NZ-$13.0439.74%
2017NZ-$9.3312.94%
2016NZ-$8.2638.84%
2015NZ-$5.95-32.88%
2014NZ-$8.86259.44%
2013NZ-$2.47-31.25%
2012NZ-$3.59

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$12.11 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$4.41-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$73.35 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$14.35-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.26-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.41-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.36-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.60-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA